Current Report Filing (8-k)

0001596062 false NONE 0001596062 2022-01-21 2022-01-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

January 21, 2022

Date of Report (Date of earliest event reported)

 

Q BioMed Inc.

(Exact name of registrant as specified in its charter)

 

Nevada	000-55535	46-4013793
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

 

c/o Ortoli Rosenstadt LLP 366 Madison Avenue, 3rd Floor New York, NY	10017
(Address of principal executive offices)	(Zip Code)

 

[phone]

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
None		None		None

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01

Entry into a Material Definitive Agreement.

 

On January 21, 2022, we entered into a Conversion Agreement with YA II PN, Ltd., the purchaser of $500,000 of convertible notes that we sold pursuant to a Securities Purchase Agreement, dated February 12. 2021. Pursuant to the Conversion Agreement, YA PN II, Ltd. agreed to convert its outstanding debenture from the Securities Purchase Agreement, including accrued and unpaid interest, into shares of the Company’s common stock at a price of $0.50 per share.

 

YA II PN, Ltd. converted its debenture totaling $527,500 into 1,055,000 shares of the Company’s common stock. Upon conversion, the Company obligations under the Securities Purchase Agreement were deemed to be satisfied and paid in full.

 

Item 3.02

Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 hereof is incorporated by reference into this Item 3.02. 

 

The securities mentioned above were issued, or will be issued, in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933, as amended (the “Act”), and Rule 506 of Regulation D promulgated under the Act.  This transaction qualified for exemption from registration because among other things, the transaction did not involve a public offering, the investor was an accredited investor and/or qualified institutional buyer, the investor had access to information about our company and its investment, the investor took the securities for investment and not resale, and we took appropriate measures to restrict the transfer of the securities.

 

Item 9.01

Financial Statements and Exhibits.

 

Exhibits.

10.1	Conversion Agreement, dated January 21, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Q BioMed Inc.
Date: January 25, 2022	By:	/s/ Denis Corin
	Name:	Denis Corin
	Title:	President and Chief Executive Officer